Topic Oleozon in patients with epidermophytosis

Phase 3

• Conditions: Epidermophytosis; Tinea; Dermatomycoses; Mycoses; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases; Bacterial Infections and Mycoses; Infection

• Registration Number: RPCEC00000289
• Lead Sponsor: ational Center For Scientific Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-09-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Patients greater than or equal to 18 years, of both sexes, who have signed their informed consent to participate in the study, with clinical diagnosis and positive mycological diagnosis of tinea pedis variety squamous, in addition patients without other infection added, virgin of treatments or with more than five days without treatment Specific topical or systemic.

Exclusion Criteria

Decompensated diabetes mellitus (fasting glucose> 7 mmol/L), diagnosed neoplasms, severe septic states, history of liver failure, history of renal failure, chronic diseases, pregnancy, concomitant use of corticosteroids, cytostatics or immunosuppressants and antibiotics, clinical history usual allergy to medications or any other special condition that at the discretion of the doctor puts your health and life at risk during the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical cure (Absence of skin lesions in the lower limbs characteristic of these conditions). Measurement time: Week, 2, 4 and, 6 of treatment.<br>Mycological Healing (Negativization of the microbiological examination). Measurement time: Sixth week of treatment.<br>Clinical and Mycological Healing (Yes when Clinical cure and Mycological Healing exists, No in other case). Measurement time: Sixth week of treatment.

Secondary Outcome Measures

Name	Time	Method
Treatment time to achieve healing (It will measure in weeks).Measurement time: Weeks 2, 4 and 6 of treatment.